NCALD

Across TCGA pan-cancer cohorts, NCALD mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NCALD data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NCALD mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NCALD expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

CCRCC, GBM, and LSCC are the cancer types where NCALD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.108	0.908	.024	10	view →
GBM	OS	Quartile	All	0.618	0.318	.007	8	view →
LSCC	DFS	Median	All	0.515	0.936	.013	5	view →
LUAD	DFS	Tertile	All	0.805	0.937	.022	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NCALD–CCRCC (DFS)

Open the CCRCC breakdown →